Harm Reduction Therp patents expiration

1. Rivive patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020343 HARM REDUCTION THERP Intranasal pharmaceutical dosage forms comprising naloxone
May, 2032

(8 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2023

Treatment: Use of intranasal naloxone for the treatment of opioid overdose


More Information on Dosage

RIVIVE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic